~~<i id='315229F560'><strike id='315229F560'><tt id='315229F560'><pre id='315229F560'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：hotspot 2025-09-27 19:27:43 - browse：325

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Covid vaccines: Private market messier than government rollout

entertainment

explore

leisure time

entertainment

focus

leisure time

AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc

WSS

As a primary care physician, here's how I hope to partner with AI

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Biogen joins immunology wave with $1.15 billion acquisition of HI

WHO recommends dropping component of many flu vaccines

FDA seeks to regulate lab

Listen: Who gets the credit for GLP

focus

Wikipedia

entertainment

Bright Health sells Medicare Advantage business to Molina

Eyeing GLP

United colonoscopy coverage change 'may cost lives,' doctors say

Shingles, which affected Dianne Feinstein, is on the rise

Psychedelics group wrestles with new pharma identity

H5N1 bird flu outbreak: Second human case reported, in Michigan

23andMe had bad news about my health. I wish a person had delivered it

After a drawn out lobbying fight, ARPA

At least 13 dead in Texas as scorching temps continue

For longer

explore

Listen: Who gets the credit for GLP

Bird flu surveillance in wastewater gets boost from consortium

Menendez indictment could see pharma lose a key ally

How one patient went off dialysis — and others can too

Researchers use wearables data and AI to predict preterm birth risk

Listen: A conversation with researcher Kevin Esvelt on biosecurity

leisure time

entertainment

focus

leisure time